Washington - PhRMA

Pharmaceutical clinical trials in Washington

Research in Your BackyardDeveloping Cures, Creating Jobs

Dots show locations of clinical trials in the state.

2 PhRMA • Pharmaceutical clinical trials in Washington

Executive Summary

Clinical Trials in Washington

• Biopharmaceutical research companies are

conducting or have conducted more than 3,600

clinical trials of new medicines in collaboration

with the state’s clinical research centers, university

medical schools and hospitals (1999 to present).

• Of the more than 3,600 clinical trials, more than

2,000 target the nation’s six most debilitating

chronic diseases—asthma, cancer, diabetes, heart

disease, mental illnesses and stroke.

Economic Benefits of Clinical Trials in Washington

According to the 2012 Annual Report of the Washington

Biotechnology & Biomedical Association, the state’s life

sciences sector—including biopharmaceutical and medi-

cal technology companies—has had a profound economic

impact:

• Job growth of 12 percent since 2007 through 2011,

compared to a 2 percent decline in jobs for all other

industries.

• Accounts for 34,000 direct jobs in the state and

supports a total of 92,000 Washington jobs.

• Washington life sciences firms produce nearly

$11 billion a year in goods and services and provide

$7 billion in personal income.

• The life sciences industry is Washington’s fifth

largest industry sector. More than 400 biopharma-

ceutical and medical technology companies and

research institutions are now in the state.

“Since cancer took the life of Gilda Radner,

we’ve witnessed amazing advancements in

cancer treatment. Clinical trials are an important

part of making those advancements possible.

Unfortunately, while nearly 20% of cancer patients

are eligible for participation in cancer clinical

trials, enrollment among adults consistently

ranges between 3-5%. More must be done to

unlock the incredible potential of clinical trials for

patients with cancer and chronic illnesses.”

— Anna Gottlieb, Gilda’s Club Seattle

3ReseaRch in YouR BackYaRd • Developing Cures, Creating Jobs

About Clinical Trials

• In the development of new medicines, clinical

trials are conducted to prove therapeutic safety

and effectiveness and compile the evidence needed

for the Food and Drug Administration (FDA) to

approve treatments.

• Clinical tests of new drugs are conducted in three

phases and account for an average of seven of the

10 to 15 years it takes to bring a new drug from

development to patients.

• Clinical trials for a given drug or treatment involve

thousands of volunteer patient participants, and the

generation of tens of thousands of pages of technical

and scientific data.

• Clinical trials are responsible for 45 to 75 percent

of the $1.2 billion average cost of developing one

new cutting-edge biotechnology medicine.

• For patients, the trials offer another potential

therapeutic option. Clinical tests may provide

a new avenue of care for some chronic disease

sufferers who are still searching for the medicines

that are best for them.

• Some trials are also conducted to compare existing

treatments and some are done to learn if a drug is

appropriate for a different patient population, such

as children. Still others are conducted to find ways

to make existing approved drugs more effective and

easier to use with fewer side effects.

• All clinical trials must be reviewed and approved

by an Institutional Review Board (IRB), an

independent committee of physicians, statisticians,

local community advocates and others to ensure

a trial is ethically conduced and patient rights are

protected.

• Clinical trial progress reports must be submitted at

least annually to the FDA and IRB.

• All facilities that conduct or support biomedical

research involving patients must comply with

federal regulations and have an IRB.

clinical trials in Washington since 1999—completed and active

all clinical trials six major chronic Diseases

3,664 2,019

Source: www.clinicaltrials.govNote: Search criteria = Washington, Phase I, II, III; industry only. Search performed 12/26/2012.

“The numbers in this report are compelling.

There is also a quiet and often untold story

behind these numbers. This story recognizes the

critical role of local volunteers whose choice to

participate in clinical trials makes it possible

for research and medical discovery to move

forward. Too many clinical trials are delayed

because not enough people realize how much

of a difference their involvement can make. This

report recognizes the thousands of courageous

men, women and children in Washington state

who step forward and partner with our research

teams to embrace the promise of a healthier

future in our lifetimes by joining a clinical trial.

For this we say, thank you!”

— Susan Adler NW Association of Biomedical Research


location asthma cancer Diabetes heart Disease mental illness stroke

Bellevue 1 — — 1 11 1

Bothell — — — — 13 —

Everett — 3 1 2 — 2

Kennewick — 11 — — 1 —

Kirkland — 1 — 1 16 —

Olympia — — 5 — — —

Renton — 1 9 1 — 1

Seattle 6 185 5 21 16 4

Spokane 6 31 17 9 6 3

Tacoma 3 27 10 10 — 5

Vancouver 2 17 — — — —

Wenatchee — 13 2 — — —

Yakima — 18 — — — —

Source: www.clinicaltrials.govNote: Search criteria = Washington, Phase I, II, II; industry only. Search performed 12/26/2012. See Appendix for detailed information about these clinical trials. The num-bers in these disease columns are not the same as the totals in the Appendix because some clinical trials are recruiting in more than one city.

clinical trials in Washington communities


Clinical Trials and Chronic Diseases

• Chronic diseases pose the greatest threats to our

nation’s health and our ability to treat and prevent

medical conditions.

• According to the Centers for Disease Control and

Prevention, today, in the United States:

• Patients with chronic diseases account for

75 cents of every dollar spent on health care.

• Chronic diseases are the leading cause of death

and disability.

• Chronic diseases are a leading driver of rising

health care costs with expenses totaling billions

of dollars every year.

• Biopharmaceutical research companies are

developing new medicines to help treat those

conditions that are taking an unprecedented toll

on American lives, and many of these medicines

are being tested today in clinical trials throughout

Washington.

• Since 1999, biopharmaceutical research companies

are sponsoring or have sponsored 2,019 clinical

trials of potential new medicines in Washington

alone for asthma, cancer, heart disease, stroke,

diabetes and mental illnesses. Of these trials, 377

are either not yet recruiting or are just now seeking

Washington patients.

• Many of the state’s clinical tests involve

collaborations with such respected local institutions

as the University of Washington, Seattle

Children’s Hospital, Swedish Hospital & Medical

Center and the Fred Hutchison Cancer Research

Center.

• Many of the medicines being clinically tested here

are new-generation biotechnology treatments.

chronic Disease all clinical trialsclinical trials

still recruiting

Asthma 66 11

Cancer 1,062 235

Diabetes 315 39

Heart Disease 154 33

Mental Illness 385 49

Stroke 37 10

total 2,019 377

Source: www.clinicaltrials.govNote: Search criteria = Washington, Phase I, II, III; industry only. Search performed 12/26/2012. Some clinical trials appear in more than one disease category.

clinical trials for top chronic Diseases


Clinical Trials in Washington

Clinical tests of new medicines are a vitally important

part of the drug development and approval process—

they account for 45 to 75 percent of the $1.2 billion

average cost of developing a new drug and are con-

ducted to determine the safety and effectiveness of that

treatment in patients.

Some trials are also conducted to compare existing treat-

ments and some are done to learn if a drug is appropriate

for a different patient population, such as children. Still

others are conducted to find ways to make existing ap-

proved drugs more effective and easier to use with fewer

side effects.

It’s essential that trials be conducted properly so that clini-

cians and drug reviewers can develop accurate assessments

of the efficacy and safety of medicines when used by

patients. The FDA is a vigilant regulatory agency and its

pharmaceutical review officers are effective in detecting

flawed information.

Questionable or confusing data can lead to lengthy delays

in product approval or outright FDA rejection of a new

drug.

Biopharmaceutical research companies are looking for the

best physicians and research institutions to meticulously

help design and conduct their clinical trials to determine

whether a medicine is safe and effective. Side effects must

be painstakingly documented and a determination made

as to whether they occur too often and are dangerous.

Clinical tests involve three phases and thousands of vol-

unteer patients and are often conducted at multiple sites

around the country. In Washington, biopharmaceutical

companies are providing funds to have trials conducted

by the state’s university medical schools, comprehensive

cancer centers and clinical trials research centers.

According to U.S. News and World Report, the University

of Washington ranked 10th among last year’s top 100

research-oriented medical schools in the United States.

clinical trials for top chronic Diseases

chronic Disease all clinical trialsclinical trials

still recruiting

Asthma 66 11

Cancer 1,062 235

Diabetes 315 39

Heart Disease 154 33

Mental Illness 385 49

Stroke 37 10

total 2,019 377

Source: www.clinicaltrials.govNote: Search criteria = Washington, Phase I, II, III; industry only. Search performed 12/26/2012. Some clinical trials appear in more than one disease category.


asthma is a debilitating condition for more than 25 mil-

lion Americans, including 7.1 million children under the

age of 18. The toll is also severe in Washington with more

than 400,000 adults and nearly 120,000 children suffer-

ing from asthma in the state, according to the Washington

State Department of Health.

Currently, 11 clinical trials of new asthma medicines are

recruiting patients in Washington. Trials are being con-

ducted at the Asthma Inc., in Seattle and MultiCare

Pulmonary Specialists in Tacoma.

cancer, the second leading cause of death in the United

States, now afflicts nearly 14 million Americans, accord-

ing to the National Cancer Institute. In Washington, more

than 37,000 new cancer cases will be diagnosed this year

and 12,390 victims in the state will die, according to the

American Cancer Society.

Currently, 235 clinical trials of new cancer medicines

are recruiting patients in Washington. Biopharmaceuti-

cal companies are collaborating on the tests with such

prominent institutions as the Fred Hutchinson Cancer

Research Center, the Swedish Cancer Institute and the

University of Washington Medical Center in Seattle, the

MultiCare Health System-Research Institute in Tacoma,

the Cascade Cancer Center in Kirkland, Providence

Regional Medical Center in Everett, Cancer Care

Northwest in Spokane and the Yakima Valley Memorial

Hospital in Yakima.

Diabetes affects 25.8 million Americans—more than

8 percent of the U.S. population—including 7 million

people who are unaware they have the disease. In Wash-

ington, more than 300,000 people have been diagnosed

with diabetes, according to the Washington State Depart-

ment of Health. In 2010, diabetes was the cause of death

of 1,497 residents.

Currently, 39 diabetes clinical tests are seeking patients

in Washington. The trials are being conducted at Seattle

Children’s Hospital and the University of Washington

Medical Center in Seattle, the MultiCare Research In-

stitute in Tacoma, Mylar Research in Lakewood, and the

Rainier Clinical Research Center in Renton.

heart disease and stroke are the first and fourth lead-

ing disease causes of death in the United States and the

second and sixth in Washington. According to the Ameri-

can Heart Association, more than 82 million Americans

are affected by these diseases. In Washington, in 2011,

more than 10,000 residents died from some form of heart

disease and 2,554 died from a stroke, according to the

Washington State Department of Health.

Currently, 33 heart disease and 10 stroke clinical tests

are seeking patients in Washington. The trials are being

conducted at Providence Sacred Heart Medical Center

in Spokane, the MultiCare Health System Research

Institute-Cardiac Study Center in Tacoma, and the

Swedish Hospital & Medical Center and the

Seattle-King County Center for Resuscitation

Research in Seattle.

mental illness affects nearly 60 million Americans

suffering from some form of the disease—from anxi-

ety to depression to schizophrenia to eating disorders.

In Washington, about 219,000 adults live with serious

mental illness and about 71,000 children live with

serious mental health conditions, according to the

National Alliance on Mental Illness.

Currently, 49 clinical trials are recruiting patients in

Washington. The trials are taking place at the Frontier

Institute in Spokane, the Summit Research Network

in Seattle, the Northwest Clinical Research Center

in Bellevue and the Eastside Therapeutic Resource in

Kirkland.

Physicians and patients can find out about clinical trials being

conducted all over the state in collaboration with local institu-

tions by accessing www.clinicaltrials.gov, a data base sponsored

by the National Institutes of Health. Information on medicines

in development is also available on www.phrma.org, the website

of the Pharmaceutical Research and Manufacturers of America

(PhRMA), under “Clinical Research and Trials.”


New Generation Medicines in Development

Many of the medicines being tested in Washington are

cutting-edge biotechnology drugs.

America’s biopharmaceutical research companies are

using biotechnology to develop hundreds of medicines

and vaccines today. And Washington is one of the states

where new-generation research and development work

is being done.

Through biotechnology, new ways are being developed to

not only more effectively treat disease, but also to predict

it and eventually preempt it.

Biotechnology medicines are developed through biologi-

cal processes using living cells or organisms, rather than

traditional chemical synthesis, the mainstay of pharmaceu-

tical development for decades.

Such novel treatments use a variety of new approaches

to treat disease. For example, a monoclonal antibody is a

laboratory-made version of the naturally occurring im-

mune system protein that binds to and neutralizes foreign

invaders. Interferons are proteins that interfere with the

ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere

with the communication process that tells a cell to pro-

duce an unwanted protein. In addition, nanotechnology is

being used in biotechnology research to provide drug-

delivery systems, new treatments and diagnostics.

Many of the medicines in clinical testing at Washington

medical schools and research centers feature these tech-

nologies. For example:

• A monoclonal antibody for the treatment of

cancer

• An antisense medicine for the treatment of

cancer.

• A recombinant fusion protein to treat diabetic

macular edema.

• A monoclonal antibody in the pipeline targets

lupus and various types of cancer.

• A therapeutic vaccine, designed to jump-start the

immune system to fight disease, is in development

for lung cancer and melanoma.

These are only a portion of the examples of new ways

the nation’s biopharmaceutical companies and Washing-

ton research institutions are working together to attack

disease. The biotechnology medicines and vaccines in

development promise to push the frontiers of science and

potentially bring more and better treatments to patients.


Conclusion

Biopharmaceutical companies’ close collaboration with

clinicians and research institutions in Washington benefits

patients, the state’s economy and the advancement of

science and patient care. Clinical trials provide stimulat-

ing biopharmaceutical research work and a reliable source

of revenue for the state’s medical schools and research

organizations and the medicines being tested are often

cutting-edge cell and protein treatments with the poten-

tial to be safer and more effective than older chemical

compound drugs.

What’s more, Washingtonians contemplating participation

in clinical trials have a wide range of choices—more than

370 tests of new medicines for the six most debilitating

chronic diseases in America are underway in communities

large and small all over the state and they are recruiting

patient volunteers.


The U.S. system of new drug approvals is perhaps the most rigorous in the world.It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical test-ing make it to human testing. And only one of those five is approved for sale.On average, it costs a company $1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.Once a new compound has been identified in the laboratory, medicines are usually devel-oped as follows:Preclinical Testing. A pharmaceutical com-pany conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the com-pound is evaluated for safety.Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test

the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annu-ally to FDA and the IRB.Clinical Trials, Phase I—Researchers test the drug in a small group of people, usually between 20 and 80 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.Clinical Trials, Phase II—The drug is given to volunteer patients, usually between 100 and 300, to see if it is effective, identify an optimal dose, and further evaluate its short-term safety.Clinical Trials, Phase III—The drug is given to a larger, more diverse patient population, often involving between 1,000 and 3,000 pa-tients (but sometime many more thousands),

to generate statistically significant evidence to confirm its safety and effectiveness. They are the longest studies, and usually take place in multiple sites around the world.New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects. Discovering and developing safe and effec-tive new medicines is a long, difficult, and expensive process. PhRMA member com-panies invested an estimated $49.5 billion in research and development in 2011.

Clinical Trials

Discovery/ Preclinical Testing Phase I Phase II Phase III FDA Phase IV

Years 6.5 1.5 2 3.5 1.5

Additionalpost-

marketingtesting

requiredby FDA

Test Population

Laboratory and animal studies

20 to 80 healthy

volunteers

100 to 300patient

volunteers

1,000 to 3,000patient

volunteersReviewprocess/approval

Purpose

Assess safety, biological activity and formulations

Determine safetyand

dosage

Evaluate effective-

ness, look for

side effects

Confirm effectiveness,

monitor adverse reactions from long-term use

Success Rate

5,000compounds evaluated

5enter trials

1approved

File

IND

at

FD

A

File

ND

A/B

LA

at

FD

A

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

The Drug Development and Approval Process

the Drug Discovery, Development and approval Process


The Good News – Many Clinical Trials are Still Recruiting

There are 377 clinical trials recruiting in Washington. These trials target the top six chronic diseases and other debilitating

diseases affecting Americans and Washingtonians.

location asthma cancer Diabetes heart Disease mental illness stroke

Bellevue 1 — — 1 11 1

Bothell — — — — 13 —

Everett — 3 1 2 — 2

Kennewick — 11 — — 1 —

Kirkland — 1 — 1 16 —

Olympia — — 5 — — —

Renton — 1 9 1 — 1

Seattle 6 185 5 21 16 4

Spokane 6 31 17 9 6 3

Tacoma 3 27 10 10 — 5

Vancouver 2 17 — — — —

Wenatchee — 13 2 — — —

Yakima — 18 — — — —

Source: www.clinicaltrials.govNote: Search criteria = Washington, Phase I, II, II; industry only. Search performed 12/26/2012. See Appendix for detailed information about these clinical trials. The numbers in these disease columns are not the same as the totals in the Appendix because some clinical trials are recruiting in more than one city.

clinical trials in Washington communities


asthma—leading institutions

conducting clinical trials

Asthma, Inc., Clinical Research Center, Seattle

MultiCare Pulmonary Specialists, Tacoma

cancer—leading institutions


Benaroya Research Institute, Seattle

Brabant Research, Monroe

Cancer Care Northwest, Spokane

Cancer Research and Biostatistics Clinical Trials

Consortium, Seattle

Cascade Cancer Center, Kirkland

Columbia Basin Hematology and Oncology, Kennewick

Comprehensive Clinical Development NW, Tacoma

Evergreen Hematology Oncology, Spokane

Fred Hutchinson Cancer Research Center, Seattle

Group Health Medical Centers, Seattle

Harrison Health Partners Bremerton Hematology &

Oncology, Bremerton

Madigan Army Medical Center, Tacoma

Medical Oncology Associates, Spokane

MultiCare Health System-Research Institute, Tacoma

Northwest Cancer Specialists, Vancouver

Northwest Medical Specialties, Tacoma

Peninsula Cancer Center, Poulsbo

Providence Regional Medical Center, Everett

Providence St. Mary Regional Cancer Center,

Walla Walla

Puget Sound Cancer Centers, Edmonds, Seattle

Rockwood Clinic, Spokane

Seattle Cancer Care Alliance, Seattle

Seattle Children’s Hospital, Seattle

Seattle Urology Research Center, Burien

Swedish Medical Center Cancer Institute, Seattle

Swedish Medical Center Neuroscience Institute, Seattle

Swedish Medical Center Tumor Institute, Seattle

University of Washington Medical Center, Seattle

VA Puget Sound Health Care, Seattle

Virginia Mason Hospital & Medical Center, Seattle

Wenatchee Valley Medical Center, Wenatchee

Yakima Valley Memorial Hospital/North Star Lodge,

Yakima

Diabetes—leading institutions/Physician


Capital Clinical Research Center, Olympia

Larry D. Stonesifer, MD, Federal Way

MultiCare Research Institute, Tacoma

Mylar Research, Lakewood

Northside Internal Medicine Associates, Spokane

Rainier Clinical Research Center, Renton

Rockwood Clinic, Tacoma


The Good News – Many Clinical Trials are Still Recruiting (continued)


Sound Medical Research, Port Orchard

Spokane Eye Clinic, Spokane


heart Disease—leading institutions


Heart Institute at Virginia Mason Hospital, Seattle

Kootenai Heart Clinics, Spokane

MultiCare Health System Research Institute/Cardiac

Study Center, Tacoma

Providence Sacred Heart Medical Center, Spokane


Seattle-King County Center for Resuscitation

Research, Seattle

Spokane Cardiology, Spokane

Swedish Hospital & Medical Center/Cardiovascular

Research, Seattle


mental illness—leading institutions/Physicians


Arifulla Kahn, Bellevue

Booth Gardner Parkinson’s Care Center, Kirkland

Claire Waltman, MD, Seattle

Eastside Therapeutic Resource, Kirkland

Frontier Institute, Spokane

Northwest Clinical Research Center, Bellevue

Scientella, LLC, Richland

Sleep Medicine Associates, Seattle

Summit Research Network, Seattle

Women’s Clinical Research Center, Seattle

stroke—leading institutions


Deaconess Medical Center, Spokane

Swedish Medical Center, Seattle


Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto www.clinicaltrials.gov, the clinical tests database of the National Institutes of Health.

asthma (11 clinical trials recruiting)

study 1:

A Study of the Effectiveness and Safety of Different

Doses of Fluticasone Propionate Taken From a Dry

Powder Inhaler (Puffer) in Adolescents and Adults Who

Have Asthma That is Not Controlled by High Dose

Inhaled Corticosteroid Asthma Medications

http://ClinicalTrials.gov/show/NCT01576718

study 2:

Efficacy of Inhaled Albuterol Spiromax® in Subjects

With Persistent Asthma


study 3:

A Safety and Efficacy Study of Inhaled R940343 in

Patients With Mild to Moderate Asthma


study 4:

Study to Evaluate the Efficacy and Safety of

Reslizumab Treatment in Patients With Moderate to

Severe Asthma


study 5:

A Study of the Effectiveness and Safety of Different

Doses of Fluticasone Propionate Taken From a Dry

Powder Inhaler in Adolescents and Adults Who Have

Asthma That is Not Controlled by Asthma Medications

Not Containing Steroids


study 6:

Evaluation of Efficacy and Safety for Single Dose of

E004 in Children With Asthma


study 7:

A Study of Lebrikizumab in Patients Whose Asthma

is Uncontrolled With Inhaled Corticosteroids and A

Second Controller Medication (LUTE)



study 8:

A Study of Lebrikizumab in Patients With

Uncontrolled Asthma Who Are on Inhaled

Corticosteroids and A Second Controller Medication

(VERSE)


study 9:

A Study of MEMP1972A in Patients With Allergic

Asthma Inadequately Controlled on Inhaled Steroids

And A Second Controller (COSTA)


study 10:

A Study of ARRY-502 in Patients With Persistent Asthma


study 11:

Efficacy and Safety of Budesonide Foam for Patients

With Active Mild to Moderate Ulcerative Proctitis or

Proctosigmoiditis


cancer (235 clinical trials recruiting)

study 1:

A Trial of Preoperative MM-121 With Paclitaxel in

HER2-negative Breast Cancer


study 2:

Anemia Treatment for Advanced Non-Small Cell Lung

Cancer (NSCLC) Patients Receiving Chemotherapy


study 3:

TRINOVA-3: A Study of AMG 386 or AMG 386

Placebo in Combination With Paclitaxel and

Carboplatin to Treat Ovarian Cancer


study 4:

Study of a Novel Indibulin Dosing Schedule for the

Treatment of Metastatic Breast Cancer


study 5:

A Study of Chemotherapy and Ramucirumab vs.

Chemotherapy Alone in Second Line Non-small Cell

Lung Cancer Patients Who Received Prior First Line

Platinum Based Chemotherapy


study 6:

Study of Denosumab as Adjuvant Treatment for

Women With High Risk Early Breast Cancer Receiving

Neoadjuvant or Adjuvant Therapy (D-CARE)


study 7:

Study of PX-866 and Docetaxel in Solid Tumors


study 8:

A Study Combining mFOLFOX6 With Tivozanib or

Bevacizumab in Patients With Metastatic Colorectal

Cancer as First Line Therapy


study 9:

The BEACON Study (Breast Cancer Outcomes With

NKTR-102)


study 10:

Continued HER2 Suppression With Lapatinib Plus

Trastuzumab Versus Trastuzumab Alone


study 11:

A Study of MDV3100 Versus Bicalutamide in Castrate

Men With Metastatic Prostate Cancer



study 12:

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks

vs. Every 12 Weeks) in Patients With Documented Bone

Metastases From Bone Cancer


study 13:

Randomized Phase II Trial of Letrozole With or

Without Dasatinib as First and Second-line Treatment

for Hormone Receptor-positive, HER2-negative

Post-menopausal Breast Cancer That is Unresectable,

Locally Recurrent or Metastatic


study 14:

A Study in Metastatic Cancer and Advanced or

Metastatic Unresectable Pancreatic Cancer


study 15:

A Study in Second Line Metastatic Colorectal Cancer


study 16:

Study for Women With Platinum Resistant Ovarian

Cancer Evaluating EC145 in Combination With Doxil®

(PROCEED)


study 17:

Sipuleucel-T in Metastatic Castrate Resistant Prostate

Cancer (CRPC) Patients Previously Treated on

Dendreon Study P-11 (NCT00779402)


study 18:

Efficacy and Safety Study of NeuVax™ Vaccine to

Prevent Breast Cancer Recurrence


study 19:

A Phase 2 Study Comparing Chemotherapy in

Combination With OGX-427 or Placebo in Patients

With Bladder Cancer


study 20:

Phase III Study of BKM120/Placebo With Fulvestrant

in Postmenopausal Patients With Hormone Receptor

Positive HER2-negative Locally Advanced or Metastatic

Breast Cancer Refractory to Aromatase Inhibitor


study 21:

A Study of Abiraterone Acetate Plus Prednisone With

or Without Exemestane in Postmenopausal Women

With Estrogen Receptor-Positive (ER+) Metastatic

Breast Cancer Progressing After Letrozole or

Anastrozole Therapy


study 22:

Study Evaluating the Safety and Efficacy Of

Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/

Bevacizumab With and Without GDC-0941 in Patients

With Previously Untreated Advanced Or Recurrent

Non-small Cell Lung Cancer


study 23:

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in

Patients With Ovarian Cancer


study 24:

Study of BMS-936558 Compared to Docetaxel in

Previously Treated Advanced or Metastatic Squamous

Cell Non-small Cell Lung Cancer (NSCLC)



study 25:

A Study of First-line Maintenance Tarceva (Erlotinib)

Versus Tarceva at Time of Disease Progression in

Patients With Advanced Non-small Cell Lung Cancer

After Chemotherapy


study 26:

A Study of Pertuzumab in Combination With

Herceptin (Trastuzumab) And Vinorelbine in First Line

in Patients With Metastatic or Locally Advanced

HER2-Positive Breast Cancer


study 27:

ARCHER 1009: A Study Of PF-00299804

(Dacomitinib) Vs. Erlotinib In The Treatment Of

Advanced Non-Small Cell Lung Cancer


study 28:

TRINOVA-1: A Study of AMG 386 or Placebo, in

Combination With Weekly Paclitaxel Chemotherapy,

as Treatment for Ovarian Cancer, Primary Peritoneal

Cancer and Fallopian Tube Cancer


study 29:

Study of Cabozantinib (XL184) Versus Mitoxantrone

Plus Prednisone in Men With Previously Treated

Symptomatic Castration-resistant Prostate Cancer


study 30:

Natural Supplements and a Special Diet in Eliminating

Growth Hormones Made Outside the Body in Patients

With Early-Stage Prostate Cancer, Breast Cancer, or

Uterine Cancer


study 31:

Study of Cabozantinib (XL184) Versus Prednisone

in Men With Metastatic Castration-resistant Prostate

Cancer Previously Treated With Docetaxel and

Abiraterone or MDV3100


study 32:

A Phase II Study to Evaluate the Efficacy of TKI258

for the Treatment of Patients With FGFR2 Mutated or

Wild-type Advanced and/or Metastatic Endometrial

Cancer


study 33:

Safety Study of PLX108-01 in Patients With Solid

Tumors


study 34:

Study of Gemcitabine + PEGPH20 vs Gemcitabine

Alone in Stage IV Previously Untreated Pancreatic

Cancer


study 35:

Evaluation of an Anti-cancer Immunotherapy

Combined With Standard Neoadjuvant Treatment in

Patients With WT1-positive Primary Invasive Breast

Cancer


study 36:

Study of MDV3100 as a Neoadjuvant Therapy for

Patients Undergoing Prostatectomy for Localized

Prostate Cancer


study 37:

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine

in Pancreatic Cancer Patients Receiving at Least 2

Prior Therapies.



study 38:

Safety and Efficacy Study of Enzalutamide Versus

Bicalutamide in Men With Prostate Cancer


study 39:

Study of Abiraterone Acetate in Patients With Advanced

Prostate Cancer


study 40:

Denosumab Compared to Zoledronic Acid in the

Treatment of Bone Disease in Subjects With Multiple

Myeloma


study 41:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed

GBM Brain Cancer


study 42:

A Study of Oral CFG920 in Patients With Castration

Resistant Prostate Cancer


study 43:

A Study of Onartuzumab (MetMAb) in Combination

With mFOLFOX6 in Patients With Metastatic

HER2-Negative Gastroesophageal Cancer


study 44:

Study Of Dacomitinib In Advanced NSCLC Patients

(Post Chemo Or Select First Line) To Evaluate

Prophylactic Intervention On Derm And GI AEs And

PRO


study 45:

Study of Pasireotide in Patients With Rare Tumors of

Neuroendocrine Origin


study 46:

A Study of Pertuzumab in Addition to Chemotherapy

and Herceptin (Trastuzumab) as Adjuvant Therapy in

Patients With HER2-Positive Primary Breast Cancer


study 47:

A Multi-arm Phase I Safety Study of BMS-936558

in Combination With Gemcitabine/Cisplatin,

Pemetrexed/Cisplatin, Carboplatin/Paclitaxel,

Bevacizumab Maintenance, Erlotinib or Monotherapy

Alone in Subjects With Stage IIIB/IV Non-small Cell

Lung Cancer (NSCLC)


study 48:

A Phase 3 Efficacy Study of a Recombinant Vaccinia

Virus Vaccine to Treat Metastatic Prostate Cancer


study 49:

EMD 525797 in Subjects With Asymptomatic or Mildly

Symptomatic Metastatic Castrate-resistant Prostate Cancer


study 50:

SPI-1005 for Prevention and Treatment of

Chemotherapy Induced Hearing Loss


study 51:

Brentuximab Vedotin in Patients With CD30-positive

Nonlymphomatous Malignancies


study 52:

A Phase 1 Dose Escalation Trial of ASG-5ME in

Pancreatic or Gastric Adenocarcinoma


study 53:

Immunotherapy Study for Surgically Resected

Pancreatic Cancer



study 54:

Efficacy and Safety of Leuprolide Acetate 22.5 mg

Depot in Treatment of Prostate Cancer


study 55:

Sativex® for Relieving Persistent Pain in Patients With

Advanced Cancer


study 56:

Trial Evaluating Dovitinib Combined With Fulvestrant,

in Postmenopausal Patients With HER2- and

HR+ Breast Cancer


study 57:

A Phase 2 Diagnostic Imaging Study With

99mTc-MIP-1404 in Men With High-Risk Prostate

Cancer Scheduled for Radical Prostatectomy (RP) and

Extended Pelvic Lymph Node Dissection (EPLND)

Compared to Histopathology


study 58:

Open-label, Phase II, Study of Everolimus Plus

Letrozole in Postmenopausal Women With ER+

Metastatic Breast Cancer


study 59:

A Study of Ramucirumab (IMC-1121B) in

Combination With Eribulin Versus Eribulin Alone in

Patients With Breast Cancer


study 60:

Study of IMC-18F1 or Ramucirumab DP in

Combination With Capecitabine or Capecitabine on

Previously Treated Breast Cancer Patients


study 61:

Study of BMS-936558 Compared to Docetaxel in

Previously Treated Advanced or Metastatic Non-

squamous NSCLC


study 62:

Cvac as Maintenance Treatment in Patients With

EOC in Complete Remission Following First-Line

Chemotherapy


study 63:

A Phase 2 Study of LY2495655 in Participants With

Pancreatic Cancer


study 64:

A Study of the Safety and Pharmacokinetics of

Escalating Doses of DSTP3086S in Patients With

Metastatic Castration-Resistant Prostate Cancer


study 65:

A Study of Avastin (Bevacizumab) in Combination

With Standard of Care Treatment in Patients With

Lung Cancer


study 66:

A Study of Onartuzumab (MetMAb) Versus Placebo in

Combination With Paclitaxel Plus Platinum in Patients

With Squamous Non-Small Cell Lung Cancer


study 67:

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel

With Placebo in Patients With Locally Recurrent or

Metastatic Breast Cancer



study 68:

Study of Palifosfamide-tris in Combination With

Carboplatin and Etoposide in Chemotherapy Naïve

Patients With Extensive-Stage Small Cell Lung Cancer

(The MATISSE Study)


study 69:

Study To Evaluate the Efficacy and Safety Of

Bevacizumab, and Associated Biomarkers, In

Combination With Paclitaxel Compared With Paclitaxel

Plus Placebo as First-line Treatment Of Patients With

Her2-Negative Metastatic Breast Cancer


study 70:

A Study of VGX-3100 DNA Vaccine With

Electroporation in Patients With Cervical Intraepithelial

Neoplasia Grade 2/3 or 3


study 71:

Trial in Squamous Non Small Cell Lung Cancer

Subjects Comparing Ipilimumab Plus Paclitaxel

and Carboplatin Versus Placebo Plus Paclitaxel and

Carboplatin


study 72:

A Study of MK-1775 in Combination With Paclitaxel

and Carboplatin Versus Paclitaxel and Carboplatin

Alone for Participants With Platinum-Sensitive Ovarian

Tumors With the P53 Gene Mutation (MK-1775-004

AM4)


study 73:

A Phase 2b Study of Modified Vaccinia Virus to Treat

Patients Advanced Liver Cancer Who Failed Sorafenib


study 74:

A Study to Evaluate the Safety and Efficacy of

Inactivated Varicella-zoster Vaccine (VZV) as a

Preventative Treatment for Herpes Zoster (HZ) and

HZ-related Complications in Adult Participants With

Solid Tumor or Hematologic Malignancy (V212-011

AM2)


study 75:

Efficacy Evaluation of TheraSphere Following Failed

First Line Chemotherapy in Metastatic Colorectal

Cancer


study 76:

SpaceOAR System Pivotal Study


study 77:

A Clinical Study in Cancer Patients to Investigate the

Potential Impact of Custirsen, on the Blood Levels of

the Chemotherapeutic Drug, Paclitaxel, When Given

Together as Part of a Treatment Regimen


study 78:

NOLAN: Naproxen or Loratadine and Neulasta


study 79:

A Study of Ramucirumab and Paclitaxel in Patients

With Solid Tumors


study 80:

A Study in Head and Neck Cancer


study 81:

Pharmacodynamic Study of Abiraterone in the

Treatment of Advanced Prostate Cancer



study 82:

Phase 2 Study of EC145 Alone Versus EC145+Docetaxel

Versus Docetaxel Alone in Participants With FR(++)

2nd Line Non Small Cell Lung Cancer


study 83:


With Bevacizumab (Avastin) Plus Platinum And

Paclitaxel or With Pemetrexed Plus Platinum in

Patients With Non-Squamous Non-Small Cell Lung

Cancer


study 84:

Study of Safety and Efficacy in Patients With Malignant

Rhabdoid Tumors (MRT) and Neuroblastoma


study 85:

A Study of Pemetrexed & Carboplatin/Cisplatin or

Gemcitabine & Carboplatin/Cisplatin With or Without

IMC-1121B in Patients Previously Untreated With

Recurrent or Advanced Non-small Cell Lung Cancer

(NSCLC)


study 86:

A Pharmacokinetic Study of Trabectedin in Patients

With Advanced Malignancies and Hepatic Dysfunction


study 87:

A Randomized, Open-label, Multicenter, Phase 3

Study to Compare the Efficacy and Safety of Eribulin

With Treatment of Physician’s Choice in Subjects With

Advanced Non-Small Cell Lung Cancer


study 88:

A Rollover Study to Provide Continued Treatment

With GSK2118436 to Subjects With BRAF

Mutation-Positive Tumors


study 89:

A Study Of PF-04449913 In Select Hematologic

Malignancies


study 90:

A Study of LY2784544 in Participants With

Myeloproliferative Neoplasms


study 91:

LUX-Head&Neck 2: A Phase III Trial of Afatinib

(BIBW 2992) Versus Placebo for the Treatment of Head

and Neck Squamous Cell Cancer After Treatment With

Chemo-radiotherapy


study 92:

Phase Ib Study of Olaparib Plus Weekly Carboplatin

and Paclitaxel in Relapsed Ovarian Cancer


study 93:

Efficacy and Safety of GS-6624 With FOLFIRI as

Second Line Treatment in Colorectal Adenocarcinoma


study 94:

A Study to Evaluate the Efficacy and Safety of GS-6624

Combined With Gemcitabine for Metastatic Pancreatic

Adenocarcinoma


study 95:

An Investigational Drug, PF-02341066, Is Being Studied

In Patients With Advanced Non-Small Cell Lung

Cancer With A Specific Gene Profile Involving The

Anaplastic Lymphoma Kinase (ALK) Gene


study 96:

Gemcitabine and ON 01910.Na in Previously Untreated

Metastatic Pancreatic Cancer



study 97:

A Phase 1 Study to Evaluate the Safety, Tolerability,

and Pharmacokinetics of MEDI0639 in Advanced Solid

Tumors


study 98:

Study of AUY922 and Cetuximab in Patients With

KRAS Wild-Type Metastatic Colorectal Cancer


study 99:

A Study to Compare the Safety and Efficacy of an

Aromatase Inhibitor in Combination With Lapatinib,

Trastuzumab or Both for the Treatment of Hormone

Receptor Positive, HER2+ Metastatic Breast Cancer


study 100:

Iodine I 131 and Pazopanib Hydrochloride in Treating

Patients With Recurrent and/or Metastatic Thyroid

Cancer Previously Treated With Iodine I 131 That

Cannot Be Removed By Surgery


study 101:

Safety Study of IL-21/Anti-PD-1 Combination in the

Treatment of Solid Tumors


study 102:

A Study to Look at How a Single Oral Dose of

14C-OSI-906 is Absorbed, Broken Down and

Eliminated in the Body


study 103:

A Study of RO5137382 (GC33) in Patients With

Advanced or Metastatic Hepatocellular Carcinoma


study 104:

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as

2nd Line Tx in Metastatic Colorectal Cancer


study 105:

Study of Everolimus, Pemetrexed, Carboplatin, and

Bevacizumab to Treat Stage IV Lung Cancer


study 106:

Vaccine Therapy in Treating Patients With Breast

Cancer


study 107:

A Study of RO5429083 in Patients With Metastatic

and/or Locally Advanced, CD44-Expressing, Malignant

Solid Tumors


study 108:

A Study of LY2940680 in Small Cell Lung Cancer


study 109:

An Extension Study of ABT-806 in Subjects With

Advanced Solid Tumors


study 110:

Safety and Efficacy of ALD518 for Reducing Oral

Mucositis in Head and Neck Cancer Subjects


study 111:

A Study of ABT-888 in Combination With Carboplatin

and Gemcitabine in Subjects With Advanced Solid

Tumors



study 112:

A Dose Finding Study With Oral LDK378 in Patients

With Tumors Characterized by Genetic Abnormalities

in Anaplastic Lymphoma Kinase (ALK)


study 113:

Intermittent Hormone Therapy in Men With Localized

Prostate Cancer After Radiation Therapy or Radical

Prostatectomy


study 114:

Open-label Study to Evaluate the Safety, PK, and PD of

MEK Inhibitor GSK1120212 in Subjects With Relapsed

or Refractory Leukemias


study 115:

Intravenous Administration of RGI-2001 in Patient

Undergoing Allogenic Hematopoietic Stem Cell

Transplantation (AHSCT)


study 116:

Intermittent Chemotherapy With or Without GM-CSF

for Metastatic HPRC


study 117:

Trial in Extensive-Disease Small Cell Lung Cancer

(ED-SCLC) Subjects Comparing Ipilimumab Plus

Etoposide and Platinum Therapy to Etoposide and

Platinum Therapy Alone


study 118:

A Study to Evaluate Pazopanib as an Adjuvant

Treatment for Localized Renal Cell Carcinoma (RCC)


study 119:

Gynaecological Follow-up of a Subset of HPV-015

(NCT00294047) Study Subjects


study 120:

Safety and Tolerability Study of GSK1120212, a MEK

Inhibitor, in Combination With Docetaxel, Erlotinib,

Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed +

Cisplatin, or Nab-Paclitaxel


study 121:

GSK1120212 Rollover Study


study 122:

Induction Chemotherapy for Locally Advanced

Squamous Cell Carcinoma of the Head and Neck


study 123:

Axitinib (AG-013736) With Or Without Dose Titration

(Increase) In Patients With Kidney Cancer


study 124:

Multiple Ascending Dose (MDX1105-01)


study 125:

Study of BMN 673, a PARP Inhibitor, in Patients With

Advanced Hematological Malignancies


study 126:

Phase 1 and 2 Study of PX-866 and Cetuximab



study 127:

Interleukin-12 Gene and in Vivo

Electroporation-Mediated Plasmid DNA Vaccine

Therapy in Treating Patients With Merkel Cell Cancer


study 128:

Treatment Extension Study for Patients Who Have

Previously Participated and Have Benefited From

Iniparib in a Clinical Trial


study 129:

A Study Of Panobinostat In Children With Refractory

Hematologic Malignancies


study 130:

A Phase 1 Study of LY2787106 in Cancer and Anemia


study 131:

Study of a Retroviral Replicating Vector to Treat

Patients Undergoing Surgery for a Recurrent

Malignant Brain Tumor


study 132:

First in Human Study to Determine the Safety,

Tolerability and Preliminary Efficacy of an

Anti-CXCR4 Antibody in Subjects With Acute

Myelogenous Leukemia and Selected B-cell Cancers


study 133:

A Study of MM-111 in Combination With Multiple

Treatments in Patients With HER2 Positive Cancer


study 134:

A Dose-finding Study of a Combination of Imatinib and

BKM120 in the Treatment of 3rd Line GIST Patients


study 135:

E7050 in Combination With Cetuximab Versus

Cetuximab Alone in the Treatment of

Platinum-Resistant Squamous Cell Carcinoma of the

Head and Neck


study 136:

An Extension Study for Patients Who Are Deriving

Benefit With CAL-101 to Continue on Treatment at the

End of the Current Study


study 137:

A Study Of PF-05082566 As A Single Agent And In

Combination With Rituximab


study 138:

Efficacy Evaluation of TheraSphere in Patients With

Inoperable Liver Cancer


study 139:

Safety and Efficacy Study for Solid Tumor Patients

Treated With Eltrombopag


study 140:

Treosulfan and Fludarabine Before Donor Stem Cell

Transplant in Treating Patients With Nonmalignant

Inherited Disorders


study 141:

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992)

Versus Erlotinib for the Treatment of Squamous Cell

Lung Cancer After at Least One Prior Platinum Based

Chemotherapy



study 142:

Study of Ramucirumab or IMC-18F1 With Docetaxel

or Docetaxel Alone as Second-Line Therapy in

Participants With Bladder,Urethra, Ureter, or Renal

Pelvis Carcinoma


study 143:

A Phase I Dose Finding and Safety Study of Oral

LDE225 in Children and a Phase II Portion to Assess

Preliminary Efficacy in Recurrent or Refractory MB


study 144:

A Study of Vemurafenib in Metastatic Melanoma

Patients With Brain Metastases


study 145:

Phase III Study of Lenalidomide and Dexamethasone

With or Without Elotuzumab to Treat Newly

Diagnosed, Previously Untreated Multiple Myeloma


study 146:

Assessment of Efficacy and Safety of Perifosine,

Bortezomib and Dexamethasone in Multiple Myeloma

Patients


study 147:

DN24-02 as Adjuvant Therapy in Subjects With High

Risk HER2+ Urothelial Carcinoma


study 148:

PF-04856884 (CVX-060) In Combination With Axitinib

In Patients With Previously Treated Metastatic Renal

Cell Carcinoma


study 149:

A Study of ARRY-520 in Patients With Relapsed or

Refractory Multiple Myeloma


study 150:

Study of Bortezomib and Dexamethasone With or

Without Elotuzumab to Treat Relapsed or Refractory

Multiple Myeloma


study 151:

Study of Elotuzumab in Combination With

Lenalidomide and Dexamethasone in Subjects With

Multiple Myeloma and Various Levels of Renal

Function


study 152:

Effect of NovoTTF-100A Together With Temozolomide

in Newly Diagnosed Glioblastoma Multiforme (GBM)


study 153:

Study of CX-4945 in Patients With Relapsed or

Refractory Multiple Myeloma


study 154:

A Phase 3 Study Comparing Oral MLN9708 Plus

Lenalidomide and Dexamethasone Versus Placebo Plus

Lenalidomide and Dexamethasone in Adult Patients

With Relapsed and/or Refractory Multiple Myeloma


study 155:

Anti-CXCR4 (BMS-936564) Alone and in Combination

With Lenalidomide/Dexamethasone or Bortezomib/

Dexamethasone in Relapsed/Refractory Multiple

Myeloma



study 156:

Study of ACY-1215 in Combination With Lenalidomide,

and Dexamethasone in Multiple Myeloma


study 157:

Phase III Study of Rindopepimut/GM-CSF in Patients

With Newly Diagnosed Glioblastoma


study 158:

Clinical Study With Blinatumomab in Pediatric

and Adolescent Patients With Relapsed/Refractory

B-precursor Acute Lymphoblastic Leukemia


study 159:

A Study of Rindopepimut/GM-CSF in Patients With

Relapsed EGFRvIII-Positive Glioblastoma


study 160:

A Safety and Efficacy Study of Carfilzomib and

Pomalidomide With Dexamethasone in Patients With

Relapsed or Refractory Multiple Myeloma


study 161:

A Phase 1 Study Evaluating the Safety and

Pharmacokinetics of ABT-199 in Subjects With

Relapsed or Refractory Chronic Lymphocytic

Leukemia and Non-Hodgkin Lymphoma


study 162:

BNC105P in Combination With Everolimus/Following

Everolimus For Progressive Metastatic Clear Cell Renal

Cell Carcinoma


study 163:

Randomized Trial of Lenalidomide, Bortezomib,

Dexamethasone vs High-Dose Treatment With SCT in

MM Patients up to Age 65


study 164:

A Safety Study of Carfilzomib With Cyclophosphamide

and Dexamethasone Prior to Autologous Stem Cell

Transplant in Patients With Newly Diagnosed Multiple

Myeloma


study 165:

Ofatumumab Versus Rituximab Salvage

Chemoimmunotherapy Followed by Autologous Stem

Cell Transplant in Relapsed or Refractory Diffuse Large

B Cell Lymphoma


study 166:

A Study to Evaluate the Safety and Efficacy of

Ustekinumab in Patients With Moderately to Severely

Active Crohn’s Disease Who Have Failed or Are

Intolerant to Tumor Necrosis Factor (TNF) Antagonist

Therapy (UNITI-1)


study 167:

ch14.18 Pharmacokinetic Study in High-risk

Neuroblastoma


study 168:

Study of BMS-936558 vs. Everolimus in Pre-Treated

Advanced Or Metastatic Clear-cell RCC


study 169:

A Study of Vemurafenib Adjuvant Therapy in Patients

With Resected Cutaneous BRAF Mutant Melanoma



study 170:

A Phase III Study of Oral LDE225 Versus (vs)

Temozolomide (TMZ) in Patients With Hedge-Hog

(Hh)-Pathway Activated Relapsed Medulloblastoma

(MB)


study 171:

A Study to Assess the Safety, Pharmacokinetics and

Effectiveness of AGS-16C3F Monotherapy in Subjects

With Renal Cell Carcinoma (RCC) of Clear Cell or

Papillary Histology


study 172:

A Phase 1b Study of SGN-75 in Combination With

Everolimus in Patients With Renal Cell Carcinoma


study 173:


With Bevacizumab Compared to Bevacizumab Alone

or Onartuzumab Monotherapy in Patients With

Recurrent Glioblastoma


study 174:

SGI-110 in the Treatment of Advanced Hepatocellular

Carcinoma (HCC)


study 175:

A Study of Ramucirumab (IMC-1121B) Drug Product

(DP) and Best Supportive Care (BSC) Versus Placebo

and BSC as 2nd-Line Treatment in Patients With

Hepatocellular Carcinoma After 1st-Line Therapy With

Sorafenib


study 176:

Phase III Trans-Arterial Chemo-Embolization (TACE)

Adjuvant HCC


study 177:

ADI-PEG 20 Versus Placebo in Subjects With Advanced

Hepatocellular Carcinoma Who Have Failed Prior

Systemic Therapy


study 178:

Safety Study of IL-21/Ipilimumab Combination in the

Treatment of Melanoma


study 179:

Phase 1 Biomarker Study of Anti-PD-1 in Advanced

Melanoma


study 180:

A Study of Trabectedin or Dacarbazine for the

Treatment of Patients With Advanced Liposarcoma or

Leiomyosarcoma


study 181:

An Efficacy and Safety Study of Oral Netupitant

and Palonosetron for the Prevention of Nausea and

Vomiting


study 182:

A Study of IMC-3G3 in Soft Tissue Sarcoma


study 183:

A Study to Provide Access to Trabectedin in Patients

With Non L-type Soft Tissue Sarcoma Who Have

Persistent or Recurrent Disease and Who Are Not

Expected to Benefit From Currently Available Standard

of Care Treatment



study 184:

Phase 3 Study to Compare the Efficacy and Safety of

Eribulin With Dacarbazine in Subjects With Soft Tissue

Sarcoma


study 185:

Trivalent Ganglioside Vaccine With Immunological

Adjuvant or Immunological Adjuvant Alone in

Metastatic Sarcoma Patients Who Are Rendered

Disease Free


study 186:

Study Evaluating Chemotherapy in Combination

With Inotuzumab Ozogamicin In Subjects With

Non-Hodgkin’s Lymphoma


study 187:

Study of US-ATG-F to Prevent Chronic Graft Versus

Host Disease (GVHD)


study 188:

A Study Of Inotuzumab Ozogamicin Plus Rituximab

For Relapsed/Refractory Aggressive Non-Hodgkin

Lymphoma Patients Who Are Not Candidates For

Intensive High-Dose Chemotherapy


study 189:

PNOC 001: Phase II Study of Everolimus for Recurrent

or Progressive Low-grade Gliomas in Children


study 190:

A Placebo-Controlled Study of Saracatinib (AZD0530)

in Patients With Recurrent Osteosarcoma Localized to

the Lung


study 191:

A Randomized, Controlled Study Evaluating the

Efficacy and Safety of GS-1101 (CAL-101) in

Combination With Ofatumumab for Previously

Treated Chronic Lymphocytic Leukemia


study 192:

Comparison of Pixantrone + Rituximab With

Gemcitabine + Rituximab in Patients With Aggressive

B-cell Non-Hodgkin Lymphoma or Follicular Grade 3

Lymphoma Who Have Relapsed After Therapy and Are

Not Eligible for Stem Cell Transplant


study 193:

A Study of RO5072759 (GA101) in Combination With

CHOP Chemotherapy in Patients With Previously

Untreated Advanced Diffuse Large B-Cell Lymphoma

(GATHER)


study 194:

A Study of DCDT2980S in Combination With

MabThera/Rituxan or DCDS4501A in Combination

With MabThera/Rituxan in Patients With



study 195:

Study Of The Effectiveness & Safety Of Lenalidomide

Versus Chlorambucil As First Line Therapy For Elderly

Patients With B-Cell CLL (The ORIGIN Trial)


study 196:

Study to Assess the Effectiveness of RCHOP With or

Without VELCADE in Previously Untreated

Non-Germinal Center B-Cell-like Diffuse Large B-Cell

Lymphoma Patients



study 197:

A Study to Evaluate the Efficacy and Safety of

Lenalidomide as Maintenance Therapy for Patients

With B-Cell Chronic Lymphocytic Leukemia (CLL)

Following Second Line Therapy


study 198:

A Study of Brentuximab Vedotin in Relapsed or

Refractory CD30-positive Non-Hodgkin Lymphoma


study 199:

Ofatumumab and Bendamustine Followed by

Maintenance Ofatumumab for Rituximab Relapsed

Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL)


study 200:

Single Agent Ofatumumab Vs. Single Agent

Rituximab in Follicular Lymphoma Relapsed After

Rituximab-Containing Therapy


study 201:

A Randomized, Double-Blind and Placebo-Controlled

Study of GS-1101 in Combination With Bendamustine

and Rituximab for Previously Treated Chronic

Lymphocytic Leukemia (CLL)


study 202:

Phase 1/2 Safety and Efficacy of PLX3397 in Adults

With Relapsed or Refractory Acute Myeloid Leukemia

(AML)


study 203:

Safety and Efficacy Study of TRU-016 Plus

Bendamustine vs. Bendamustine in Relapsed Chronic

Lymphocytic Leukemia


study 204:

A Phase 3 Study of Ibrutinib (PCI-32765) Versus

Ofatumumab in Patients With Relapsed or Refractory

Chronic Lymphocytic Leukemia


study 205:

A Study to Investigate the Efficacy and

Safety of Bendamustine Compared With

Bendamustine+RO5072759 (GA101) in Patients With

Rituximab-Refractory, Indolent Non-Hodgkin’s

Lymphoma (GADOLIN)


study 206:

A Study of CSL362 in Patients With CD123+ Acute

Myeloid Leukemia Currently in Remission


study 207:

A Study of AC220 Given After Transplant in Subjects

With Acute Myeloid Leukemia (AML)


study 208:

Study Evaluating Inotuzumab Ozogamicin In Acute

Lymphocytic Leukemia


study 209:

Randomized Study of ON 01910.Na in Refractory

Myelodysplastic Syndrome Patients With Excess Blasts


study 210:

Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101)

in Relapsed or Refractory Hodgkin Lymphoma


study 211:

A Study of Brentuximab Vedotin in Adults Age 60 and

Above With Newly Diagnosed Hodgkin Lymphoma (HL)



study 212:

A Randomized, Double-Blind and Placebo-Controlled

Study of GS-1101 in Combination With Rituximab for

Previously Treated Chronic Lymphocytic Leukemia

(CLL)


study 213:

A Phase II Study of Dasatinib in Children and

Adolescents With Newly Diagnosed Chronic Phase

CML or With Ph+ Leukemias Resistant or Intolerant

to Imatinib


study 214:

Efficacy and Safety of Decitabine as Epigenetic

Priming With Induction Chemotherapy in Pediatric

Acute Myelogenous Leukemia (AML) Subjects


study 215:

A Phase 3 Study to Evaluate Marqibo® in the

Treatment of Subjects ≥ 60 Years Old With Newly

Diagnosed ALL


study 216:

Study to Investigate CAL-101 in Combination With

Chemotherapeutic Agents and CD20 mAb in Patients

With Relapsed or Refractory Indolent B-cell

Non-Hodgkin’s Lymphoma, Mantle Cell Lymphoma

or Chronic Lymphocytic Leukemia


study 217:

A Study of Escalating Doses of DCDS4501A in Patients

With Relapsed or Refractory B-Cell Non-Hodgkin’s

Lymphoma and Chronic Lymphocytic Leukemia

and DCDS4501A in Combination With Rituximab in

Patients With Relapsed or Refractory B-Cell



study 218:

Pediatric Philadelphia Positive Acute Lymphoblastic

Leukemia


study 219:

Phase I Clinical Study of CWP232291 in Acute Myeloid

Leukemia Patients


study 220:

Alisertib (MLN8237) or Investigator’s Choice in

Patients With Relapsed/Refractory Peripheral T-Cell

Lymphoma


study 221:

Clinical Study With Blinatumomab in Patients With

Relapsed/Refractory B-precursor Acute Lymphoblastic

Leukemia (ALL)


study 222:

A Study of the Safety and Preliminary Efficacy of

Oral Midostaurin (PKC412) in Relapsed or Refractory

Pediatric Leukemia


study 223:

Combined Rituximab and Lenalidomide Treatment for

Untreated Patients With Follicular Lymphoma


study 224:

A Extension Study of GS-1101 for Patients With

Chronic Lymphocytic Leukemia Who Participated in

GS-US-312-0116


study 225:

A Moderate to Severe Rheumatoid Arthritis Study



study 226:

Trial of Nelarabine, Etoposide and Cyclophosphamide

in Relapsed T-cell ALL and T-cell LL


study 227:

Multi-center Study of Myeloablative Allo Stem Cell

Transplant for Non-remission AML Using CloBu4

Regimen


study 228:

Phase 1 Nilotinib in Steroid Dependent/Refractory

Chronic Graft Versus Host Disease


study 229:

A Phase I Study of AC220 for Children With Relapsed

or Refractory Acute Lymphoblastic Leukemia or Acute

Myelogenous Leukemia


study 230:

Everolimus With Multiagent Re-Induction

Chemotherapy in Pediatric Patients With ALL


study 231:

A Trial of Temsirolimus With Etoposide and

Cyclophosphamide in Children With Relapsed Acute

Lymphoblastic Leukemia and Non-Hodgkins Lymphoma


study 232:

Myelodysplastic Syndromes (MDS) Event Free Survival

With Iron Chelation Therapy Study


study 233:

A Placebo-controlled Study of Efficacy & Safety of 2

Trough-ranges of Everolimus Asadjunctive Therapy in

Patients With Tuberous Sclerosis Complex (TSC) &

Refractory Partial-onset Seizures


study 234:

An Open-label, Multi-center, Expanded Access Study

of Pasireotide s.c. in Patients With Cushing’s Disease


study 235:

Intravenous Acetaminophen for Craniotomy Patients


Diabetes (39 clinical trials recruiting)

study 1:

A Study in Patients With Type 2 Diabetes Mellitus


study 2:

Comparison of the Efficacy and Safety of Two

Different Dose Adjustment Regimens for Insulin

Degludec/Insulin Aspart in Subjects With Type 2

Diabetes Mellitus Previously Treated With Insulin

Glargine


study 3:

A Study of BMS-512148 (Dapagliflozin) in Patients

With Type 2 Diabetes With Inadequately Controlled

Hypertension on an ACEI or ARB and an Additional

Antihypertensive Medication


study 4:

A Study of BMS-512148 (Dapagliflozin) in Patients

With Type 2 Diabetes With Inadequately Controlled

Hypertension on an Angiotensin-Converting Enzyme

Inhibitor (ACEI) or Angiotensin Receptor Blocker

(ARB)



study 5:

A Study in Patients With Type I Diabetes Mellitus


study 6:

BI 10773 Cardiovascular Outcome Event Trial in Type 2

Diabetes Mellitus Patients.


study 7:

A Study in Participants With Type 2 Diabetes Mellitus


study 8:

Cardiovascular Outcomes Study of Alogliptin in

Subjects With Type 2 Diabetes and Acute Coronary

Syndrome


study 9:

Efficacy and Safety Study of DiaPep277 in Newly

Diagnosed Type 1 Diabetes Adults


study 10:

Efficacy and Safety of Liraglutide Versus Placebo as

add-on to Existing Diabetes Medication in Subjects

With Type 2 Diabetes and Moderate Renal Impairment


study 11:

A Study of Aleglitazar in Patients With Type 2 Diabetes

Mellitus Who Have Not Previously Received

Anti-Hyperglycemic Therapy


study 12:

A 16 Weeks Study on Efficacy and Safety of Two Doses

of Empagliflozin (BI 10773) (Once Daily Versus Twice

Daily) in Patients With Type 2 Diabetes Mellitus and

Preexisting Metformin Therapy


study 13:

Comparison of a New Formulation of Insulin Glargine

With Lantus in Patients With Type 1 Diabetes Mellitus


study 14:

The Effect of Liraglutide Versus Placebo When Added

to Basal Insulin Analogues With or Without Metformin

in Subjects With Type 2 Diabetes


study 15:

The Effect of Insulin Degludec in Combination With

Liraglutide and Metformin in Subjects With Type 2

Diabetes Qualifying for Treatment Intensification


study 16:

The Efficacy of Insulin Degludec/Liraglutide in

Controlling Glycaemia in Adults With Type 2 Diabetes

Inadequately Controlled on GLP-1 Receptor Agonist

and Metformin Therapy


study 17:

A Trial Comparing the Efficacy, Patient-reported

Outcomes and Safety of Insulin Degludec 200 U/mL

vs Insulin Glargine in Subjects With Type 2 Diabetes

Mellitus Requiring High-dose Insulin


study 18:

Safety Study of Mesenchymal Precursor Cells in Type 2

Diabetes


study 19:

Study to Evaluate the Efficacy, Safety, Tolerability, and

Pharmacokinetics of Saxagliptin as Monotherapy in

Pediatric Patients With Type 2 Diabetes



study 20:

Researching Cardiovascular Events With a Weekly

Incretin in Diabetes (REWIND)


study 21:

Safety and Efficacy Study of Empagliflozin and

Metformin for 24 Weeks in Treatment Naive Patients

With Type 2 Diabetes


study 22:

Exenatide Study of Cardiovascular Event Lowering

Trial (EXSCEL): A Trial To Evaluate Cardiovascular

Outcomes After Treatment With Exenatide Once

Weekly In Patients With Type 2 Diabetes Mellitus


study 23:

A Study Comparing Dulaglutide With Insulin Glargine

on Glycemic Control in Participants With Type 2

Diabetes (T2D) and Moderate or Severe Chronic

Kidney Disease (CKD)


study 24:

Comparison of a New Formulation of Insulin

Glargine With Lantus in Patients With Type 2 Diabetes

on Non-insulin Antidiabetic Therapy


study 25:

A Study of MK-3102 in Participants With Type 2

Diabetes Mellitus With Chronic Kidney Disease or

Kidney Failure on Dialysis (MK-3102-019 AM2)


study 26:

Addition of MK-3102 to Participants With Type 2

Diabetes Mellitus Who Have Inadequate Glycemic

Control on Combination Therapy With Glimepiride

and Metformin (MK-3102-022)


study 27:

A Study Evaluating Safety and Efficacy of BIOD-123

Compared to Insulin Lispro (Humalog®)


study 28:

A Phase 2 Study to Evaluate the Safety and Efficacy of

CTP-499 in Type 2 Diabetic Nephropathy Patients


study 29:

A Study of Aleglitazar in Combination With Metformin

in Patients With Type 2 Diabetes Mellitus Who Are

Inadequately Controlled With Metformin Alone


study 30:

Phase 2b Multicenter, Randomized, Double-Blind,

Placebo- and Active-Controlled, Parallel-Group Study

to Assess the PD Response and Safety of Three Dose

Levels of Glymera Injection Following 20 Weeks of

Weekly SC Dosing in Adults With T2DM


study 31:

Outpatient Study to Evaluate Safety and Effectiveness

of the Low Glucose Suspend Feature


study 32:

The Effectiveness of Continuous Glucose Monitoring

in Diabetes Treatment for Infants and Young Children


study 33:

A Phase 2, Placebo-Controlled Study To Evaluate The

Efficacy And Safety Of PF-00489791 In Patients With

Type 2 Diabetes And Overt Nephropathy



study 34:

A Study on The Potential of Aleglitazar to Reduce

Cardiovascular Risk in Patients With Stable

Cardiovascular Disease and Glucose Abnormalities


study 35:

Treatment of Neuropathic Pain Associated With

Diabetic Peripheral Neuropathy


study 36:

Evaluation of Cardiovascular Outcomes in Patients

With Type 2 Diabetes After Acute Coronary Syndrome

During Treatment With AVE0010 (Lixisenatide)


study 37:

A Study to Test Safety and Efficacy of Baricitinib in

Participants With Diabetic Kidney Disease


study 38:

Study to Evaluate MK-6096 in the Treatment of Painful

Diabetic Neuropathy (PDN) in Adults (MK-6096-021

AM1)


study 39:

Prompt Panretinal Photocoagulation Versus

Ranibizumab+Deferred Panretinal Photocoagulation

for Proliferative Diabetic Retinopathy


heart Disease (33 clinical trials recruiting)

study 1:

Efficacy and Safety of Targeted Intramyocardial

Delivery of Auto CD34+ Stem Cells for Improving

Exercise Capacity in Subjects With Refractory Angina


study 2:

Prevention of Cardiovascular Events (eg, Death From

Heart or Vascular Disease, Heart Attack, or Stroke)

in Patients With Prior Heart Attack Using Ticagrelor

Compared to Placebo on a Background of Aspirin


study 3:

Echocardiography Guided Cardiac Resynchronization

Therapy (EchoCRT)


study 4:

Safety and Efficacy Continued Access Study of the

Medtronic CoreValve® System in the Treatment of

Symptomatic Severe Aortic Stenosis in Very High Risk

Subjects and High Risk Subjects Who Need Aortic

Valve Replacement


study 5:

A Study of Genetically Targeted Enzyme Replacement

Therapy for Advanced Heart Failure


study 6:

Clinical Evaluation of the Blazer® Open-Irrigated

Catheter for Treatment of Type 1 Atrial Flutter


study 7:

RED-HF™ Trial—Reduction of Events With

Darbepoetin Alfa in Heart Failure Trial


study 8:

Cardiovascular Outcomes Study of Alogliptin in Subjects

With Type 2 Diabetes and Acute Coronary Syndrome



study 9:

Evaluation of Cardiovascular Outcomes in Patients

With Type 2 Diabetes After Acute Coronary Syndrome

During Treatment With AVE0010 (Lixisenatide)


study 10:

INcrease Of VAgal TonE in CHF


study 11:

A Study Comparing Cardiovascular Effects of

Ticagrelor and Clopidogrel in Patients With Peripheral

Artery Disease


study 12:

Cardiovascular Risk Reduction Study (Reduction in

Recurrent Major CV Disease Events)


study 13:

Ranolazine for Incomplete Vessel Revascularization

Post-Percutaneous Coronary Intervention (PCI)


study 14:

ST Monitoring to Detect Acute Coronary Syndrome

Events in Implantable Cardioverter Defibrillator

Patients


study 15:

Clinical Outcomes Assessment of the MitraClip

Therapy Percutaneous Therapy for High Surgical Risk

Patients


study 16:

AngelMed for Early Recognition and Treatment of

STEMI


study 17:

Premium Migraine Trial


study 18:

Post-Myocardial Infarction Remodeling Prevention

Therapy


study 19:

Determining the Feasibility of Spinal Cord

Neuromodulation for the Treatment of Chronic Heart

Failure


study 20:

An Efficacy, Safety and Tolerability Study of

Ixmyelocel-T Administered Via Transendocardial

Catheter-based Injections to Subjects With Heart

Failure Due to Ischemic Dilated Cardiomyopathy

(IDCM)


study 21:

Effect of Otamixaban Versus Unfractionated Heparin

+ Eptifibatide in Patients With Unstable Angina/Non

ST Elevation Myocardial Infarction Undergoing Early

Invasive Strategy


study 22:

Cardiox Shunt Detection Technology Study


study 23:

ABLATE AF Registry Trial


study 24:

Study of Pasireotide in Patients With Rare Tumors of

Neuroendocrine Origin



study 25:

The PARTNER II Trial: Placement of AoRTic

TraNscathetER Valves


study 26:

AMR-001 Versus Placebo Post ST Segment Elevation

Myocardial Infarction


study 27:

Vest Prevention of Early Sudden Death Trial and VEST

Registry


study 28:

A Study Exploring Two Treatment Strategies in

Patients With Atrial Fibrillation Who Undergo Catheter

Ablation Therapy


study 29:

A Study to Evaluate the Effect of Ranolazine and

Dronedarone When Given Alone and in Combination

in Patients With Paroxysmal Atrial Fibrillation

(HARMONY)


study 30:

Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide

in Pediatric Critical Care Patients


study 31:

Amiodarone, Lidocaine or Neither for Out-Of-Hospital

Cardiac Arrest Due to Ventricular Fibrillation or

Tachycardia


study 32:

A Study to Evaluate the Safety and Efficacy of AC607

for the Treatment of Kidney Injury in Cardiac Surgery

Subjects


study 33:

Cardiovascular Safety of Febuxostat and Allopurinol in

Patients With Gout and Cardiovascular Comorbidities


mental illness (49 clinical trials recruiting)

study 1:

Study of the Safety and Efficacy of Two Fixed Doses of

OPC-34712 as Adjunctive Therapy in the Treatment of

Adults With Major Depressive Disorder (the Polaris Trial)


study 2:

Study of the Safety and Efficacy of Fixed Dose

OPC-34712 as Adjunctive Therapy in the Treatment of

Adults With Major Depressive Disorder (the Pyxis Trial)


study 3:

Dose-optimization in Adolescents Aged 13-17 Diagnosed

With Attention-deficit/Hyperactivity Disorder (ADHD)

Using Extended-release Guanfacine HCl


study 4:

Adult Attention Deficit Hyperactivity Disorder


study 5:

An Open-Label Safety Study of Memantine in

Pediatric Patients With Autism, Asperger’s Disorder,

or Pervasive Developmental Disorder Not Otherwise

Specified (PDD-NOS)



study 6:

A Study of Mifepristone vs. Placebo in the Treatment

of Patients With Major Depression With Psychotic

Features


study 7:

Safety and Efficacy of Cariprazine as an Adjunctive to

Antidepressant Therapy in Major Depressive Disorder


study 8:

Open-label Study to Compare Hospitalization

Rates of Schizophrenic Patients Treated With Oral

Antipsychotics Versus IM Depot Aripiprazole


study 9:

Efficacy and Safety of Ramelteon Sublingual in Adult

Patients With Acute Depressive Episodes Associated

With Bipolar I Disorder


study 10:

Extension Study of Asenapine {P06107 (NCT01244815)}

for Pediatric Bipolar Disorder (P05898 AM3)


study 11:

Study to Evaluate the Efficacy and Safety of

Armodafinil Treatment (150 mg/Day) as Adjunctive

Therapy in Adults With Major Depression Associated

With Bipolar I Disorder


study 12:

Efficacy and Safety of Ramelteon Sublingual as

Adjunctive Therapy for Maintenance Treatment of

Bipolar I Disorder in Adult Patients


study 13:

Efficacy and Safety of Asenapine Treatment for

Pediatric Bipolar Disorder {P06107 Has an Extension

(P05898; NCT01349907}(P06107 AM3)


study 14:

Long-term Safety and Tolerability of BMS-820836 in

the Treatment of Patients With Treatment Resistant

Major Depression


study 15:

Efficacy of LuAA21004 on Cognitive Dysfunction in

Major Depressive Disorder


study 16:

Safety, Efficacy and Tolerability of Vilazodone in

Generalized Anxiety Disorder (VLZ-MD-05)


study 17:

A Study of RO4917838 in Patients With Persistent,

Predominant Negative Symptoms of Schizophrenia

(NN25310)


study 18:

An Efficacy, Safety and Tolerability of Cariprazine as an

Adjunctive Treatment to Antidepressant Therapy (ADT)

in Patients With Major Depressive Disorder (MDD)


study 19:

Safety, Tolerability, and Efficacy of Cariprazine for

Patients With Bipolar Depression


study 20:

A Study to Evaluate ALKS 5461 in Subjects With Major

Depressive Disorder (MDD)



study 21:

A Study of RO4917838 (Bitopertin) in Patients With

Persistent, Predominant Negative Symptoms of

Schizophrenia (WN25309)


study 22:

A Study of Flexible or Fixed Dose LLY2216684 as

Adjunctive Treatment for Participants With Major

Depressive Disorder Who Have Had a Partial Response

to Selective Serotonin Reuptake Inhibitor (SSRI)

Treatment


study 23:

A 6-Month Extension Study To The B2061032 Study

To Evaluate The Safety, Tolerability, And Efficacy Of

DVS SR In The Treatment Of Child And Adolescent

Outpatients With MDD


study 24:

SPD489 in Adults Aged 18-55 Years With Moderate to

Severe Binge Eating Disorder


study 25:

A Study of RO4917838 in Patients With Sub-optimally

Controlled Symptoms of Schizophrenia (NN25307)


study 26:

A 6-Month Open-Label Extension Study to the

B2061014 Study to Evaluate the Safety, Tolerability and

Efficacy of DVS SR in the Treatment of Children and

Adolescents With MDD


study 27:

Study of the Effectiveness of Three Different Doses

of OPC-34712 in the Treatment of Adults With Acute

Schizophrenia


study 28:

A Study to Assess the Effect and Safety of AZD6765 in

Patients With Major Depressive Disorder


study 29:

Study of Paliperidone Palmitate 3 Month and 1 Month

Formulations for the Treatment of Patients With

Schizophrenia


study 30:

PEARL Schizophrenia Maintenance


study 31:

A Study Of DVS SR In Treatment Of Children And

Adolescent Outpatients With MDD


study 32:

NBI-98854 for the Treatment of Tardive Dyskinesia

in Subjects With Schizophrenia or Schizoaffective

Disorder (KINECT Study)


study 33:

The Safety and Efficacy of AF-219 in Female Subjects

With Interstitial Cystitis /Bladder Pain Syndrome


study 34:

Effect of Lu AA21004 Versus Escitalopram on Sexual

Functioning in Adults With Well-Treated Major

Depressive Disorder


study 35:

Efficacy and Safety Study of SPD489 in Combination

With an Antidepressant in the Treatment of Adults With

Major Depressive Disorder



study 36:

A Study Of DVS SR In Treatment Of Children And

Adolescent Outpatients With MDD


study 37:

Fixed Dose Efficacy and Safety Study of Asenapine for

the Treatment of Schizophrenia in Adolescents (P05896

AM2)


study 38:

Efficacy & Safety Study of Oral Aripiprazole in

Adolescents With Schizophrenia


study 39:

Efficacy and Safety of TBS-2 Testosterone Gel in

Pre-Menopausal Women With Acquired Female

Orgasmic Disorder


study 40:

A Twelve Week, Open Label Extension Study in Patients

With Schizophrenia


study 41:

Safety and Efficacy Study of IPX159 in Restless Legs

Syndrome (RLS)


study 42:

Flexible Dose, Long-term Safety Study of Asenapine

for the Treatment of Schizophrenia in Adolescents

(P05897 AM2 EXT)


study 43:

A Study in Prevention of Re-emergence of Depression

Symptoms


study 44:

Safety and Efficacy Study of Ramelteon (TAK-375)

Tablets for Sublingual Administration (SL) in Adults

With Bipolar 1 Disorder


study 45:

SPD489 in Adults Aged 18-55 Years With Moderate to

Severe Binge Eating Disorder


study 46:

A Study of RO4917838 (Bitopertin) in Patients With

Sub-optimally Controlled Symptoms of Schizophrenia

(WN25306)


study 47:

Safety and Tolerability Study of Oral OPC-34712 as

Maintenance Treatment in Adults With Schizophrenia


study 48:

Effect of PBT2 in Patients With Early to Mid Stage

Huntington Disease


study 49:

Efficacy and Safety of Fixed Doses of BMS 820836 in

the Treatment of Patients With Treatment Resistant

Major Depression


stroke (10 clinical trials recruiting)

study 1:

Study of ALD-401 Via Intracarotid Infusion in Ischemic

Stroke Subjects


study 2:

Efficacy and Safety Study of Desmoteplase to Treat

Acute Ischemic Stroke (DIAS-4)


study 3:

Prevention of Cardiovascular Events (eg, Death From

Heart or Vascular Disease, Heart Attack, or Stroke)

in Patients With Prior Heart Attack Using Ticagrelor

Compared to Placebo on a Background of Aspirin


study 4:

Phase 3, Randomized, Placebo-Controlled,

Double-Blinded Trial of the Combined Lysis of

Thrombus With Ultrasound and Systemic Tissue

Plasminogen Activator (tPA) for Emergent

Revascularization in Acute Ischemic Stroke


study 5:

Carotid Stenting vs. Surgery of Severe Carotid Artery

Disease and Stroke Prevention in Asymptomatic

Patients (ACT I)


study 6:

A Study Comparing Cardiovascular Effects of

Ticagrelor and Clopidogrel in Patients With Peripheral

Artery Disease


study 7:

Cardiovascular Risk Reduction Study (Reduction in

Recurrent Major CV Disease Events)


study 8:

Cardiovascular Outcomes Study of Alogliptin in

Subjects With Type 2 Diabetes and Acute Coronary

Syndrome


study 9:

Cardiovascular Safety of Febuxostat and Allopurinol in

Patients With Gout and Cardiovascular Comorbidities


study 10:

Gadobutrol Enhanced MRA of the Supra-aortic Vessels


Pharmaceutical research and manufacturers of america 950 F street, nW, Washington, Dc 20004

www.phrma.org

place union bug here

Date post:	10-Feb-2022
Category:	Documents
Upload:	others
View:	4 times
Download:	0 times

Washington - PhRMA

Documents